The global protein engineering market Outlook was valued at USD 3.6 Billion in 2024 and is projected to reach USD 8.2 Billion by 2033, exhibiting a CAGR of 9.5% during the forecast period of 2025-2033. North America leads the market with a 40.6% share, driven by innovations in AI-driven automation that enhance protein modeling, drug discovery, and enzyme optimization. Government funding accelerating academic research also propels advancements in protein therapeutics and synthetic biology.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Protein Engineering Market Key Takeaways

• Current Market Size: USD 3.6 Billion in 2024
• CAGR: 9.5%
• Forecast Period: 2025-2033
• North America dominates the market with a 40.6% share in 2024.
• Artificial intelligence (AI) automates protein modeling and industrial enzyme optimization, boosting market expansion.
• Government funding fuels academic research and innovation in protein therapeutics and synthetic biology.
• Rising prevalence of chronic and protein-deficient diseases increases demand for engineered proteins in therapeutics.
• Advancements in genetic engineering and synthetic biology enable precise protein modifications for pharmaceutical and industrial uses.

Request for a Free Sample Report: https://www.imarcgroup.com/protein-engineering-market/requestsample

Market Growth Factors

Government financial support and university research play a major role in speeding up the protein engineering market by sponsoring the base studies on protein structure, function, and bioengineering applications. Public research grants and programs for federal funding are the main promoters of the creation of new protein-based therapeutics and industrial enzymes. The collaboration between the research institutions and biotech companies allows the fast translation of these discoveries into practical uses. Besides that, government-supported projects also facilitate synthetic biology and AI-driven protein modeling, which in turn, help in drug discovery and targeted therapy development. These factors together have a positive effect on the market, providing innovation and commercialization, thus, expanding it. 

Protein engineering market is being revolutionized by artificial intelligence (AI) and automation which lead to higher efficiency, accuracy, and scalability. Machine learning algorithms are used to predict protein structure, which is the major help in drug discovery and biopharmaceutical development. Deep learning models are employed to analyze large biological datasets with the aim of identifying novel protein sequences, meanwhile, automated high-throughput screening enables rapid selection of engineered protein candidates thus, lowering the expenses and time required. Additionally, the use of robotics and AI-integrated laboratory automation make the processes of protein purification, characterization, and large-scale biomanufacturing more efficient and streamlined. These technological advancements are among the major factors that trigger market demand growth. 

The protein engineering market is supported by the rise in investments into synthetic biology and the market's response to the prevalence of diseases caused by protein deficiency. The global synthetic biology market size reached USD 18.5 billion in 2024 and is forecasted to grow to USD 66.7 billion by 2033 with a CAGR of 15.3% from 2025 to 2033. Engineered proteins that exhibit increased stability and have the functionality tailored are the most effective way of solving malnutrition and hereditary protein-related disorders. Biopharmaceutical companies design recombinant proteins for diseases such as cystic fibrosis and hemophilia. The increasing awareness, demand for plant-based proteins, and progress in genetic engineering are the factors that are fueling this market and at the same time facilitating protein expression, bioavailability, and therapeutic efficacy. 

Market Segmentation

Analysis by Product & Services:

• Instruments: Comprise 53.2% share in 2024; include analytical instruments enabling precise protein characterization, purification, sequencing, and high-throughput screening.
• Reagents: Not explicitly detailed in the source beyond listing.
• Services and Software: Not explicitly detailed in the source beyond listing.

Analysis by Protein Type:

• Insulin: Not specifically elaborated upon.
• Monoclonal Antibodies: Hold 24.5% market share in 2024; key in targeted drug treatments for cancer and autoimmune disorders with enhanced specificity and stability.
• Coagulation Factors: Not specifically elaborated upon.
• Vaccines: Not specifically elaborated upon.
• Growth Factors: Not specifically elaborated upon.
• Others: Not specifically elaborated upon.

Analysis by Technology:

• Irrational Protein Design: Not detailed in the source.
• Rational Protein Design: Largest market share; utilizes computational modeling and AI algorithms to effectively predict and optimize protein structures, enhancing drug development.

Analysis by End User:

• Pharmaceutical and Biotechnology Companies: Largest share (45.3% in 2024); drive innovation in therapeutic proteins and biologics.
• Academic Research Institutes: Not detailed beyond listing.
• Contract Research Organizations: Not detailed beyond listing.

Regional Insights

In 2024 North America will be the major player with a 40.6% share of the global protein engineering market and this is the region that benefits most from having big biotech and pharmaceutical companies, strong government funding, AI-driven innovations, and a vibrant biopharmaceutical industry. Besides that, growth will be further supported by fast regulatory approvals and high demand for biologics, which will attract investments to North America and consolidate its position as the leader in the protein engineering global space.

Recent Developments & News

• November 2024: Cradle Bio secured USD 73 million in Series B funding, raising total investments beyond USD 100 million. Its AI-powered platform advances protein engineering in therapeutics, diagnostics, agriculture, chemicals, and food, collaborating with 21 clients including top pharmaceutical firms.
• October 2024: Avenue Biosciences raised EUR 2.3 million (USD 2.38 million) in seed funding led by Voima Ventures and angel investors to enhance protein production efficiency in biopharmaceuticals and advance gene therapies, monoclonal antibodies, and mRNA vaccines.
• September 2023: Scala Biodesign from Tel Aviv secured USD 5.5 million seed funding led by TLV Partners for its AI-driven protein engineering platform.
• April 2023: Adaptyv Bio launched a protein foundry with robotics and synthetic biology to validate AI-designed proteins, addressing challenges in translating models into functional proteins.

Key Players

• Abzena Limited
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• Bruker Corporation
• Codexis Inc.
• DH Life Sciences, LLC
• GenScript
• Merck KGaA
• Novo Nordisk A/S
• Protomer Technologies (Eli Lilly and Company)
• Revvity, Inc.
• Thermo Fisher Scientific Inc.
• Waters Corporation

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302